The Supreme Court is expected to rule in April on an appeal by Novartis Vaccines & Diagnostics for arbitration in a dispute with Aventis Pharma, a subsidiary of French company Sanofi Aventis, over the marketing of an anti-rabies vaccine.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
